A Study of Chidamide With AZA in MRD Positive AML After Transplant

This study tests a combination of two drugs — chidamide (a type of epigenetic therapy) and azacitidine (AZA, a chemotherapy agent) — for patients with acute myeloid leukemia (AML) who have had a bone marrow transplant but still have detectable residual cancer cells (called MRD-positive, meaning the cancer hasn't been fully eliminated). **You may be eligible if...** - You are 18 or older and have been diagnosed with AML - You have had an allogeneic (donor) stem cell transplant - You have detectable residual disease (MRD-positive) after transplant - Your general health is adequate (ECOG score ≤3) and your expected survival is at least 3 months - You are willing to use contraception **You may NOT be eligible if...** - You are allergic to the study drugs - You have active infections, HIV, hepatitis B, or hepatitis C - You have another active cancer - You are pregnant or breastfeeding - You are already participating in another clinical trial Talk to your doctor to see if this trial is right for you.